EA011554B1 - Стабильные жидкие композиции плазмидной днк - Google Patents

Стабильные жидкие композиции плазмидной днк Download PDF

Info

Publication number
EA011554B1
EA011554B1 EA200700656A EA200700656A EA011554B1 EA 011554 B1 EA011554 B1 EA 011554B1 EA 200700656 A EA200700656 A EA 200700656A EA 200700656 A EA200700656 A EA 200700656A EA 011554 B1 EA011554 B1 EA 011554B1
Authority
EA
Eurasian Patent Office
Prior art keywords
plasmid dna
composition
concentration
buffer
solution
Prior art date
Application number
EA200700656A
Other languages
English (en)
Russian (ru)
Other versions
EA200700656A1 (ru
Inventor
Франсис БЛАНШ
Мишель Кудер
Николя Мастрали
Тьерри Гиллемэн
Давид Гайак
Original Assignee
Сентелион
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Сентелион filed Critical Сентелион
Publication of EA200700656A1 publication Critical patent/EA200700656A1/ru
Publication of EA011554B1 publication Critical patent/EA011554B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA200700656A 2004-09-17 2005-09-19 Стабильные жидкие композиции плазмидной днк EA011554B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (2)

Publication Number Publication Date
EA200700656A1 EA200700656A1 (ru) 2007-10-26
EA011554B1 true EA011554B1 (ru) 2009-04-28

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700656A EA011554B1 (ru) 2004-09-17 2005-09-19 Стабильные жидкие композиции плазмидной днк

Country Status (14)

Country Link
EP (1) EP1791945A1 (ja)
JP (1) JP2008512997A (ja)
KR (1) KR20070058621A (ja)
CN (1) CN101040041A (ja)
AU (1) AU2005284244A1 (ja)
BR (1) BRPI0515553A (ja)
CA (1) CA2579340A1 (ja)
EA (1) EA011554B1 (ja)
IL (1) IL181753A0 (ja)
MX (1) MX2007003214A (ja)
NO (1) NO20071946L (ja)
NZ (1) NZ553914A (ja)
TN (1) TNSN07087A1 (ja)
WO (1) WO2006029908A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
US20180036409A1 (en) * 2014-12-29 2018-02-08 Bonac Corporation Composition containing nucleic acid molecule stably
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
CN111225984A (zh) * 2017-08-25 2020-06-02 硕腾服务有限责任公司 核酸探针、使用uv光将核酸固定到固体载体的方法、包括固定化核酸探针的固体载体以及包括固体载体的测试装置
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
JP2021536241A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 核酸を検出する方法
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
WO2023182614A1 (ko) * 2022-03-24 2023-09-28 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037750A1 (fr) * 1998-01-21 1999-07-29 Aventis Pasteur Procede et dispositif de lyse cellulaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
EP1242441A4 (en) * 1999-12-17 2004-04-14 Merck & Co Inc POLYNUCLEOTIDE VACCINES EXPRESSING CODON-OPTIMIZED NEF HIV-1 PROTEIN AND MODIFIED HIV-1 NEF PROTEIN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037750A1 (fr) * 1998-01-21 1999-07-29 Aventis Pasteur Procede et dispositif de lyse cellulaire

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Hints for optimum elution of DNA from QIAprep and QIAquick spin columns" QIAGENNEWS, 'Online! no. 4, 1998, XP002361651, Retrieved from the Internet: URL:http://www1.qiagen.com/literature/qiag ennews/0498/984hints.pdf>'retrieved on 2006-01-03! the whole document *
ANCHORDOQUY T.J. ET AL.: "Physical stability of nonviral plasmid-based therapeutics". JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 89, no. 3, March 2000 (2000-03), pages 289-296, XP002311803, ISSN: 0022-3549 *
CARON A. ET AL.: "HUMAN FGF-1 GENE TRANSFER PROMOTES THE FORMATION OF COLLATERAL VESSELS AND ARTERIOLES IN ISCHEMIC MUSCLES OF HYPERCHOLESTEROLEMIC HAMSTERS". JOURNAL OF GENE MEDICINE, WILEY, US, vol. 6, no. 9, 26 April, 2004 (2004-04-26), pages 1033-1045, XP009037918, ISSN: 1099-498X, the whole document *
EON-DUVAL A.: "Large-scale manufacturing of plasmid DNA for gene therapy and DNA vaccination - Part 1: The suitability of current techniques to purify plasmid without adding RNase". BIOPHARM INTERNATIONAL, 'Online! 1 August, 2003 (2003-08-01), XP002361654, Retrieved from the Internet: URL:http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?1d=73856>'retrieved on 2005-12-14! *
EON-DUVAL A.: "Large-scale manufacturing of plasmid DNA for gene therapy and DNA vaccination - Part 2: Toward an RNAse-free downstream process - a review". BIOPHARM INTERNATIONAL, 'Online! 1 September, 2003 (2003-09-01), XP002361653, Retrieved from the Internet: URL:http://www.biopharminternational.com/b1 opharm/article/articleDetail.jsp?id=73886>'retrieved on 2006-01-03! the whole document *
EVANS R.K. ET AL.: "Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies". JOURNAL OF PHARMACEUTICAL SCIENCES. JAN 2000, vol. 89, no. 1, January 2000 (2000-01), pages 76-87, XP002361656, ISSN: 0022-3549 *
HERWEIJER H. ET AL.: "Progress and prospects: naked DNA gene transfer and therapy". GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 10, 2003, pages 453-458, XP002903156, ISSN: 0969-7128 *
LYUBCHENKO Y.L. ET AL.: "Visualization of supercoiled DNA with atomic force microscopy in situ". PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 21 JAN., 1997, vol. 94, no. 2, 21 January, 1997 (1997-01-21), pages 496-501, XP002361655, ISSN: 0027-8424 *
MOUNT CLARE N. ET AL.: "The influence of physico-chemical and process conditions on the physical stability of plasmid DNA complexes using response surface methodology". BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY. JUN 2003, vol. 37, no. Pt 3, June 2003 (2003-06), pages 225-234, XP002361657, ISSN: 0885-4513 *
POXON S.W. ET AL.: "A BIOFUNCTIONAL ASSAY TO STUDY PRL-CMV PLASMID DNA FORMULATION STABILITY". PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, BETHESOA, MD, US, vol. 53, no. 6, November 1999 (1999-11), pages 314-317, XP009058916, ISSN: 1079-7440 *
SCHLEEF MARTIN ET AL.: "Animal-free production of ccc-supercoiled plasmids for research and clinical applications". THE JOURNAL OF GENE MEDICINE. FEB 2004, vol. 6, Suppl 1, February 2004 (2004-02), pages S45-S53, XP002361652, ISSN: 1099-498X, the whole document *
WALTHER WOLFGANG ET AL.: "Stability analysis for long-term storage of naked DNA: impact on nonviral in vivo gene transfer". ANALYTICAL BIOCHEMISTRY. 15 JUL., 2003, vol. 318, no. 2, 15 July, 2003 (2003-07-15), pages 230-235, XP002361658, ISSN: 0003-2697 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение

Also Published As

Publication number Publication date
CA2579340A1 (en) 2006-03-23
WO2006029908A1 (en) 2006-03-23
KR20070058621A (ko) 2007-06-08
IL181753A0 (en) 2007-07-04
CN101040041A (zh) 2007-09-19
NO20071946L (no) 2007-05-29
EP1791945A1 (en) 2007-06-06
MX2007003214A (es) 2007-10-11
JP2008512997A (ja) 2008-05-01
TNSN07087A1 (en) 2008-06-02
EA200700656A1 (ru) 2007-10-26
AU2005284244A1 (en) 2006-03-23
BRPI0515553A (pt) 2008-07-29
NZ553914A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
EA011554B1 (ru) Стабильные жидкие композиции плазмидной днк
AU2005233309B2 (en) Method for purifying plasmid DNA
US20070111221A1 (en) Method of preparation for pharmaceutical grade plasmid DNA
Durland et al. Manufacturing and quality control of plasmid-based gene expression systems
JP2021500072A (ja) 血友病ａに対する遺伝子編集用組成物及び方法
Carnes et al. Plasmid DNA manufacturing technology
AU722909B2 (en) Method for the production of a therapeutic DNA
EP2246413A2 (en) Method for purifying plasmid DNA having pharmaceutical quality
US20220364078A1 (en) Mrna large scale synthesis and purification
Kelly MINIREVIEW: Perspectives on plasmid‐based gene therapy: challenges for the product and the process
Douzandegan et al. Optimization of kyse-30 esophagus cancer cell line transfection using lipofectamine 2000
WO2023242425A1 (en) Compositions and methods for circular rna affinity purification
ZA200602244B (en) Method of preparation of pharmaceutically grade plasmid DNA
Channel NAKED DNA: METHODS
Santos Production and Purification of DNA G-quadruplex using pPH600 plasmid
dos Santos Production and Purification of Dna G-Quadruplex Using pPH600 Plasmid
MXPA98010328A (en) Terapeut dna production procedure

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU